Amici Capital’s United Therapeutics UTHR Stock Holding History

Amici Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-49,700	Closed	-$7.78M	–	129
2015 Q4	$7.78M	Buy	+49,700	New	+$7.23M	0.55%	45

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Amici Capital's UTHR Position: Q1 2017 in Review

Amici Capital sold out of United Therapeutics (UTHR) in Q1 2017, closing a stake of 81,032 shares — an estimated $11.6M sold.

Amici Capital first reported a position in UTHR in Q2 2013 and held it in 14 quarters. The position peaked at $165M in Q1 2015. 411 funds tracked by Wall St. Rank hold UTHR as of Q1 2017.

Amici Capital reported no remaining United Therapeutics position as of Q1 2017 after selling out during the quarter.
Amici Capital sold 81,032 United Therapeutics shares in Q1 2017, an estimated $11.6M.
Amici Capital first reported a position in United Therapeutics in Q2 2013 and held it in 14 quarters.
Amici Capital's United Therapeutics position peaked at $165M in Q1 2015.
411 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2017.

Based on Amici Capital's 13F filing for Q1 2017.